Welcome!

News Feed Item

Spinal Stenosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Stenosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Spinal Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Stenosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Stenosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Sucampo Pharmaceuticals, Inc. 31
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 31
Mesoblast Limited 32
Clinical Trial Overview of Mesoblast Limited 32
Zimmer Holdings, Inc. 33
Clinical Trial Overview of Zimmer Holdings, Inc. 33
United Therapeutics Corporation 34
Clinical Trial Overview of United Therapeutics Corporation 34
Nissan Chemical Industries, Ltd. 35
Clinical Trial Overview of Nissan Chemical Industries, Ltd. 35
LTT Bio-Pharma Co., Ltd. 36
Clinical Trial Overview of LTT Bio-Pharma Co., Ltd. 36
KT&G Corporation 37
Clinical Trial Overview of KT&G Corporation 37
Kaken Pharmaceutical Co., Ltd. 38
Clinical Trial Overview of Kaken Pharmaceutical Co., Ltd. 38
Biomet, Inc. 39
Clinical Trial Overview of Biomet, Inc. 39
Clinical Trial Overview of Top Institutes / Government 40
Seoul National University Hospital 40
Clinical Trial Overview of Seoul National University Hospital 40
Keio University 41
Clinical Trial Overview of Keio University 41
Hamamatsu University School of Medicine 42
Clinical Trial Overview of Hamamatsu University School of Medicine 42
University of Pittsburgh 43
Clinical Trial Overview of University of Pittsburgh 43
Vanderbilt University 44
Clinical Trial Overview of Vanderbilt University 44
Leiden University Medical Center 45
Clinical Trial Overview of Leiden University Medical Center 45
Yonsei University 46
Clinical Trial Overview of Yonsei University 46
Dartmouth-Hitchcock Medical Center 47
Clinical Trial Overview of Dartmouth-Hitchcock Medical Center 47
Emory University 48
Clinical Trial Overview of Emory University 48
Federal University of Sao Paulo 49
Clinical Trial Overview of Federal University of Sao Paulo 49
Five Key Clinical Profiles 50
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sucampo Pharmaceuticals, Inc., 2014* 31
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mesoblast Limited, 2014* 32
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Zimmer Holdings, Inc., 2014* 33
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by United Therapeutics Corporation, 2014* 34
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nissan Chemical Industries, Ltd., 2014* 35
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by LTT Bio-Pharma Co., Ltd., 2014* 36
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by KT&G Corporation, 2014* 37
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaken Pharmaceutical Co., Ltd., 2014* 38
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biomet, Inc., 2014* 39
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 40
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014* 41
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 42
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 43
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014* 44
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 45
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 46
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dartmouth-Hitchcock Medical Center, 2014* 47
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 48
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2014* 49

List of Figures

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69


To order this report: Spinal Stenosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
To leverage Continuous Delivery, enterprises must consider impacts that span functional silos, as well as applications that touch older, slower moving components. Managing the many dependencies can cause slowdowns. See how to achieve continuous delivery in the enterprise.
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
We all know the latest numbers: Gartner, Inc. forecasts that 6.4 billion connected things will be in use worldwide in 2016, up 30 percent from last year, and will reach 20.8 billion by 2020. We're rapidly approaching a data production of 40 zettabytes a day – more than we can every physically store, and exabytes and yottabytes are just around the corner. For many that’s a good sign, as data has been proven to equal money – IF it’s ingested, integrated, and analyzed fast enough. Without real-ti...
"There's a growing demand from users for things to be faster. When you think about all the transactions or interactions users will have with your product and everything that is between those transactions and interactions - what drives us at Catchpoint Systems is the idea to measure that and to analyze it," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York Ci...
I wanted to gather all of my Internet of Things (IOT) blogs into a single blog (that I could later use with my University of San Francisco (USF) Big Data “MBA” course). However as I started to pull these blogs together, I realized that my IOT discussion lacked a vision; it lacked an end point towards which an organization could drive their IOT envisioning, proof of value, app dev, data engineering and data science efforts. And I think that the IOT end point is really quite simple…
As companies gain momentum, the need to maintain high quality products can outstrip their development team’s bandwidth for QA. Building out a large QA team (whether in-house or outsourced) can slow down development and significantly increases costs. This eBook takes QA profiles from 5 companies who successfully scaled up production without building a large QA team and includes: What to consider when choosing CI/CD tools How culture and communication can make or break implementation
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
Redis is not only the fastest database, but it is the most popular among the new wave of databases running in containers. Redis speeds up just about every data interaction between your users or operational systems. In his session at 19th Cloud Expo, Dave Nielsen, Developer Advocate, Redis Labs, will share the functions and data structures used to solve everyday use cases that are driving Redis' popularity.
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it ...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Is your aging software platform suffering from technical debt while the market changes and demands new solutions at a faster clip? It’s a bold move, but you might consider walking away from your core platform and starting fresh. ReadyTalk did exactly that. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue and over a decade of audio conferencing product development to start an innovati...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...